Patents by Inventor Vincenzo Cannata
Vincenzo Cannata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8318763Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4)alkyl, benzyloxy, mono- and di-(C1-3)alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4)alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl(C1-4). In addition, processes to obtain these compounds are described.Type: GrantFiled: May 27, 2009Date of Patent: November 27, 2012Assignee: Alfa Wassermann S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Mahena Folegatti, Paola Righi, Vincenzo Cannata, Goffredo Rosini
-
Publication number: 20120258166Abstract: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin ? are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.Type: ApplicationFiled: June 19, 2012Publication date: October 11, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20120214989Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: May 3, 2012Publication date: August 23, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20120202989Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.Type: ApplicationFiled: April 16, 2012Publication date: August 9, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20120203000Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: April 16, 2012Publication date: August 9, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Patent number: 8183367Abstract: The present invention relates to methods of preparing polymorphic Form A of bazedoxifene acetate and polymorphic Form A prepared by such methods.Type: GrantFiled: February 11, 2009Date of Patent: May 22, 2012Assignee: Wyeth LLCInventors: Paolo Andreella, Giuseppe Barreca, Francesco Tasinato, Massimo Verzini, Marco Demo, Fabio Bassan, Vincenzo Cannata, Giorgio Soriato, Roberto Brescello, Pietro Allegrini, Livius Cotarca
-
Patent number: 8173801Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: GrantFiled: March 4, 2011Date of Patent: May 8, 2012Assignee: Alfa Wassermann, S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Patent number: 8158644Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.Type: GrantFiled: March 4, 2011Date of Patent: April 17, 2012Assignee: Alfa Wassermann, S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Patent number: 8158781Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: GrantFiled: March 4, 2011Date of Patent: April 17, 2012Assignee: Alfa Wassermann, S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20120035202Abstract: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin ? are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.Type: ApplicationFiled: October 17, 2011Publication date: February 9, 2012Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20110160448Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20110160449Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20110152516Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.Type: ApplicationFiled: March 4, 2011Publication date: June 23, 2011Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20110086871Abstract: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin ? are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.Type: ApplicationFiled: November 29, 2010Publication date: April 14, 2011Applicant: ALFA WASSERMANN, S.P.A.Inventors: Giuseppe Claudio VISCOMI, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Patent number: 7923553Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: GrantFiled: May 13, 2008Date of Patent: April 12, 2011Assignee: Alfa Wassermann, S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Patent number: 7906542Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.Type: GrantFiled: May 13, 2008Date of Patent: March 15, 2011Assignee: Alfa Wassermann, S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Patent number: 7902206Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.Type: GrantFiled: May 13, 2008Date of Patent: March 8, 2011Assignee: Alfa Wassermann, S.p.A.Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
-
Publication number: 20110034719Abstract: The present invention relates to a new process for the preparation of the (S)-naproxen 4-nitrooxybutyl ester and to new intermediates obtained and used therein. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active compounds such as (S)-naproxen 4-nitrooxybutyl ester. The invention also relates to the use of (S)-naproxen 4-nitrooxybutyl ester prepared according to the process of the present invention for the manufacturing of a medicament for the treatment of pain.Type: ApplicationFiled: October 22, 2010Publication date: February 10, 2011Applicant: NicOx S.A.Inventors: Aldo BELLI, Vincenzo CANNATA, Telly FONDUCA, Martin HEDBERG, Andreas WESTERMARK, Marco VILLA
-
Publication number: 20100267654Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4)alkyl, benzyloxy, mono- and di-(C1-3)alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4)alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl(C1-4). In addition, processes to obtain these compounds are described.Type: ApplicationFiled: May 27, 2009Publication date: October 21, 2010Applicant: ALFA WASSERMAN, S.P.A.Inventors: Giuseppe C. VISCOMI, Manuela CAMPANA, Mahena FOLEGATTI, Paolo RIGHI, Vincenzo CANNATA, Goffredo ROSINI
-
Patent number: 7759517Abstract: The present invention relates to a process for the preparation of gabapentin and, more in particular, to a method of synthesis of 1,1-cyclohexane acetic acid monoamide, an intermediate used in the preparation of gabapentin, comprising the basic hydrolysis reaction of ?, -diaminocarbonyl-?,?-pentamethylene glutarimide.Type: GrantFiled: June 22, 2005Date of Patent: July 20, 2010Assignee: Zach System S.P.A.Inventors: Marco Villa, Maurizio Paiocchi, Katiuscia Arrighi, Francesco Corcella, Vincenzo Cannata, Giorgio Soriato, Massimo Verzini